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doi:10.1016/j.jalz.200dence and offers a unifying conceptual framework for dependence in AD. Clinicians typically charac-
terize AD by symptomatic impairments in three domains: cognition, function, and behavior. From
a patient’s perspective, changes in these domains, individually and in concert, ultimately lead to in-
creased dependence and loss of autonomy. Examples of dependence in AD range from a need for re-
minders (early AD) to requiring safety supervision and assistance with basic functions (late AD).
Published literature has focused on the clinical domains as somewhat separate constructs and has given
limited attention to the concept of patient dependence as a descriptor of AD progression. This article
presents the concept of dependence on others for care needs as a potential method for translating the
effect of changes in cognition, function, and behavior into a more holistic, transparent description of
AD progression.
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Alzheimer’s disease (AD), the most common form of de-
mentia, is a progressive neurodegenerative disorder charac-
terized by loss of memory and cognition, declining ability
to perform activities of daily living (ADL), changes in per-
sonality and behavior, and increased use of health care re-
sources and medical services. An estimated 27 million
persons worldwide are currently living with AD; this numberthor. Tel.: 650-794-2534; Fax: 650-794-2504.
eibman@janimm.com.
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9.09.004is expected to quadruple to more than 106 million by 2050,
with 1 in 85 persons living with the disease [1,2]. In addition,
AD places a considerable economic burden on the families of
patients and on society. In the United States alone, AD is es-
timated to cost approximately $80 billion per year, making it
this country’s third most costly disease [3].
AD can be described in a variety of ways. Clinicians
tend to focus on cognition, function, or behavior in their
descriptions (with each specialty selecting its preferred con-
struct and measurement). The cognitive feature that is most
commonly associated with the disease is memory impair-
ment, although decision-making, judgment, spatialserved.
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might also be affected. Functional impairment in AD is typ-
ically referred to as disability in everyday functioning that
results primarily from cognitive impairment, with notable
losses in the ability to perform ADL. In addition, changes
in personality and behavior are also common in patients
with AD and might include aggression, wandering, apathy,
and motor restlessness. These changes can be socially dis-
ruptive, can create high levels of caregiver stress and bur-
den, and can also affect a patient’s ability to perform
ADL [4].
Few attempts have been made to integrate and model the
domains of cognition, function, and behavior [5,6]. Earlier at-
tempts to describe the progression of AD have focused pri-
marily on discrete measures of cognitive function [7].
Although changes in cognition are the hallmark of dementia,
especially in early disease, they are not the only symptom
and, from an economic perspective, are not the sole drivers
of the use of resources such as caregiver time, medical
care, and nursing home placement [8].
Furthermore, as noted by Loveman et al [9], the literature
provides limited and conflicting information on typical AD
progression pathways in each of the three domains, and the
variety of discrete measures that are used to describe dis-
ease-associated changes might further complicate models
of progression. In addition, the method used to track the pro-
gression of AD might affect how patients are treated during
the course of the disease and whether the treatments are
viewed as successful [10]. For example, after attempting ap-
propriate care of an AD patient who is repetitive and agitated,
clinicians might opt to prescribe a medication that causes se-
dation. If this intervention is assessed strictly on the basis of
agitation, it might be considered a success, even though the
lives of both the patient and caregiver might now be less re-
warding [11]. Because patients often experience different
levels of disrupted behavior during the course of AD, the
challenge is to manage behavioral decline without adversely
affecting the functional and cognitive abilities of the patient
at the time of the behavioral disturbances [10]. Tracking
the progression of AD by focusing on a single aspect of the
disease (eg, behavior) might mean that other important as-
pects (eg, function, cognition) might not be sufficiently ad-
dressed. A broader measure or concept of the overall
impact of AD progression would address this issue by reflect-
ing at least some of the negative effects of pharmacologic
treatment as well as the positive outcomes.
A broader measurement of AD progression would also
better integrate the concerns of individuals who are directly
affected by the disease, specifically the patients and their
loved ones. Although cognitive test scores provide clinicians
with quantitative measures of memory and other mental func-
tions, persons with AD might be more concerned with the
overall effect of the disease than with its impact on individual
domains [12,13]. Likewise, individuals who are concerned
with resource allocation and health care costs tend to measure
AD progression in terms of the patient’s direct health carecosts as well as living arrangements (eg, home versus an
assisted living facility versus a nursing facility); living
arrangements are easily assessed, and costs can be easily dif-
ferentiated across locations. However, a patient’s living situ-
ation is a function of multiple factors that might or might not
be related to the severity of AD. As a result, living environ-
ments do not provide a transparent, meaningful description
of the overall impact of the disease for patients, caregivers,
or clinicians. Although alternative measures of caregiver bur-
den, such as the Zarit Burden Interview [14], provide a broad
indicator of the effect of caregiving, these tools do not explic-
itly measure changes in patient disease severity in a transpar-
ent manner. In other words, a useful measure of AD
progression must not only be broad, but it must also convey
the effect of AD progression in a way that is meaningful to
multiple audiences.
We propose in this article that dependence, or the level of
assistance required by a patient with AD, should be used as
a construct for assessing the effect of AD treatment. Its cor-
relate, independence, is an attractive measure for assessing
disease progression because it has been shown to decline
over time [15], is associated with other domains such as cog-
nition and/or function [16], and is easily assessed/measured
during both short and long periods. Similarly, a patient’s
level of dependence logically is related (directly and indi-
rectly) to the degree of impairment in the individual domains
of cognition, function, and behavior as well as to other factors
that limit a patient’s abilities. Mapping of AD progression as
stages of increasing dependence on others would provide pa-
tients, families, and other decision makers with a better idea
of current and future service needs and help quantify the im-
pact of any treatments intended to delay this progression.
Describing AD progression as a process of increasing de-
pendence on others would not replace current (or future) clin-
ical measures (cognitive, functional, behavioral), but instead
it would be a complementary measure that would allow trans-
lation of those end points into a common language for non-
clinical audiences to use when they assess the impact of
AD and the potential benefits of interventions. Thus, it might
be beneficial to include a measure of dependence alongside
clinical end points in clinical trials, descriptive studies, regis-
tries, and other types of studies that explore AD and the effect
of its treatment. Furthermore, continued discussion of such
a concept in the scientific literature would be of value to cli-
nicians who are not currently involved in clinical trials but are
responsible for the day-to-day care of AD patients and their
loved ones.
The remainder of this article discusses the concept of de-
pendence and reviews the literature on the subject as an initial
attempt to explore the usefulness of characterizing AD pro-
gression in terms of increasing dependence.
Promoting independence or avoiding increased depen-
dence previously has been highlighted as a worthy goal for
the field of dementia care [17]. However, the multiplicity
of terms, tools, and operational definitions used to describe














Fig. 1. Dependence: Conceptual framework.
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apeutic impact.
If dependence is to be accepted as a measure of the impact
of AD progression, some degree of consensus must be
reached on the appropriate terminology and on its relation-
ship to other constructs, its operational definition, and the in-
struments used to measure it. For example, dependence, as
a construct, should reflect the level of assistance needed by
a patient, not necessarily the level of assistance that is pro-
vided. Dependence differs from measures of care service
(eg, the amount of caregiver time provided), which reflect
not only patient need but also constraints on supply (eg,
amount of caregiver time available, availability of care facil-
ities, and patient and family financial resources). In this arti-
cle, dependence is defined as the amount of care required
from others (according to text from the Dependence Scale
[16]). This definition was selected over a dichotomous mea-
sure (eg, independent versus dependent [18]) because focus-
ing on overall care needs allows for translation of multiple
facets of the disease into a single measure, and using a scale
with multiple levels provides more granularity for measuring
changes over time. Our primary objective was to review the
current literature on dependence to establish a consensus on
and recommendations for incorporating dependence into AD
therapeutic and outcomes research. We describe the concept
of dependence in AD and its relationship to other commonly
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Fig. 2. Impacts of impairments in cognition, function, and behavior on pa-
tient dependence on others.2. Dependence: Conceptual framework
Dependence in AD can be characterized as the measurable
impact of changes in cognition, function, and behavior that
result in an increased need for assistance. Although these do-
mains measure different aspects of the impact of AD, they
have an inter-related and aggregate effect (Fig. 1). Cognitive
deficits are initially subtle/mild effects that might require pa-
tients to seek assistance with social activities (this need for
assistance might correspond to limitations in handling com-
munity affairs and home and hobbies as measured on the
Clinical Dementia Rating scale [19]). Over time, cognitive
deficits might lead to increased reliance on others for coping
with memory-related impairments (eg, keeping appoint-
ments), disorientation (including maintaining proper tempo-
ral/spatial orientation), executive impairments that lessen the
patient’s ability to manage finances or medications, and fi-
nally, apraxia (ie, difficulty executing complex coordinated
movements), which might be associated with memory, judg-
ment and problem solving, and orientation categories on the
Clinical Dementia Rating [19]. Functional impairment,
which is operationally defined as a patient’s inability to per-
form specific activities, directly translates to dependence on
others and to the loss of functional autonomy. When patients
with AD can no longer dress themselves, they will be depen-
dent on caregivers to complete parts of their everyday rou-
tines. The behavioral sequelae of AD vary but mightinclude changes such as apathy, irritability, depression, anx-
iety, restlessness, agitation, and aggression. For example,
wandering often leads to increased personal risk of injury
and the need for management strategies that involve the
extended caregiving community. Although behavioral symp-
toms vary among individuals, they might generally lead to in-
creased assistance needs (eg, supervision to minimize harm
to the patient or, possibly, other individuals). For example,
Murman et al [20] found that neuropsychiatric symptoms,
as measured by the Neuropsychiatric Inventory, were signif-
icantly correlated with a measure of dependence (the Depen-
dence Scale), with changes in the Neuropsychiatric Inventory
score accounting for 22% of the variation in dependence
level.
Dependence can also be depicted to share a temporal rela-
tionship with changes in cognition, function, and behavior.
As Fig. 2 illustrates, the relative contributions of cognitive,
functional, and behavioral impairments on the overall level
of dependence would be expected to change over time, as
the disease progresses and as the relationship between the pa-
tient and his or her environment changes. For example, in
early AD/mild cognitive impairment, changes in cognition
(eg, the patient becomes forgetful and/or confused in social
situations) might be the primary contributor to changes in
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to driving, financial management) would make only a mini-
mal contribution to increased dependence in the early stages
but would be expected to play a larger role with the passage
of time and disease progression. Behavioral issues, on the
other hand, tend to be more difficult to predict; even patients
with mild cognitive impairment might experience depres-
sion, apathy, or anxiety, which might make patients more dif-
ficult to care for and might lead to a decrease in their ability to
care for themselves and therefore to increased dependence on
others. In all cases, the trend is toward greater dependence on
others, whether it is primarily caused by changes in cogni-
tion, function, or behavior.
It should be noted that a person’s level of dependence
might be further influenced by factors other than those related
to AD severity. For example, comorbid conditions, physical
handicaps, or environmental factors might play an important
role in defining an overall level of dependence on others for
care needs. However, the primary focus of this article is to ex-
plore the concept of dependence as it relates to AD, ie, how
the definition of dependence could be operationalized to fo-
cus primarily on the relationship between changes in AD
symptomatology and changes in patient reliance on others
for care needs. Furthermore, for the purpose of this discus-
sion, dependence is considered to be a separate construct
from disability; the latter is a broader measure of the general
health and well-being of a person beyond merely his or her
AD symptomatology/severity.
Previous attempts to characterize dependence either have
focused on function or have defined a small number of dis-
crete stages (eg, independent versus dependent), whereas
the dependence framework described herein has the advan-
tage of being able to characterize the complete range of the
disease’s impact and severity. Because the transition from
completely independent to completely dependent occurs on
a continuum, measures of dependence should not be charac-
terized as a dichotomous quantity or as an arbitrarily limited
number of discrete levels, as has been the case with previous
measures [15,18,21–23]. Furthermore, when changes in cog-
nition, function, and behavior are translated into a single
overall measure of disease impact, patients, caregivers, and
providers might gain a clearer understanding of the typical
course of the disease.3. Discussion of independence/dependence in the
literature
The idea of associating AD with the loss of independence
is not new. A number of researchers have described AD pro-
gression in this way. For example, Bullock and Hammond
[24] described the natural course of AD as a gradual loss of
independence, dividing it into four stages: mild (patient has
cognitive deficits that might necessitate retirement from
work, but he or she remains capable of living independently);
moderate (need for assistance with ADL and personality
changes mean that the patient might not be able to safelylive alone); severe (patient has lost the ability to ambulate in-
dependently and can no longer eat without assistance); and
for patients who live long enough, terminal, which is charac-
terized by the inability to walk (even with assistance) or to
communicate with others [24]. Much of this description
comes from an earlier article by Volicer [25], who presented
a similar description of progressive dementia.
Barbas and Wilde [26] reviewed the impact of dementia
from a legal perspective and noted that the loss of compe-
tency, which typically occurs as the disease progresses be-
yond the early stages, creates unique challenges and
interferes with a patient’s ability to live independently. Fi-
nally, Woods [17] dedicated an entire article to the need for
promoting well-being and independence among people
with dementia and noted the lack of methods for measuring
these traits in this population.
Although articles identifying loss of independence as an
important feature of AD have been in the public domain
for many years, the lack of a concise operational definition
of dependence, as well as the lack of a specific measurement
approach, has likely limited the attention that has been given
to this concept. The next section provides an overview of in-
struments that have been developed to measure changes in
dependence in patients with AD.3.1. Broad measures of dependence: Published
instruments
A MEDLINE search of all indexed journals published in
English from 1980 through 2008 was conducted by using
the terms dementia, Alzheimer’s disease, dependence, and in-
dependence. This initial query identified 521 potentially rel-
evant articles containing these search terms. After excluding
articles focused on alcohol or drug dependence and those that
included the search terms in a way that was unrelated to the
current review (eg, context dependent, pH dependent, inde-
pendent variable), a working set of 98 articles remained.
Articles related to purely functional measures (eg, mea-
sured only ADL) were then excluded (n 5 41, see Appen-
dix), as were measures of subjective caregiver burden (eg,
Zarit Burden Interview, n5 10; see Appendix), to focus pri-
marily on instruments purported to measure the level of
patient dependence on others for care needs.
Of the remaining 47 articles that discussed dependence/in-
dependence and dementia, a semistructured review of ab-
stracts was conducted to further exclude articles that did
not discuss specific instruments or research activities (n 5
29; see Appendix), which left 18 articles that described
some measure of dependence in dementia or AD.
The reference lists from articles obtained through the
MEDLINE search were also reviewed for pertinent sources.
This literature search indicated that relatively few instru-
ments have been developed to measure dependence in
patients with AD (Table 1) [15,16,18,27–34].
The Record of Independent Living (RIL) is a 37-item in-
strument designed to evaluate cognitive decline in elderly
Table 1
Instruments for measuring degree of dependence
Instrument Target population Administration No. of items Comment Reference citation(s)
RIL Patients with mild to
severe dementia and
behavioral problems
Informant-completed 37 Beyond the original
publication, there is
limited information
available on use of this
instrument
Weintraub [27]
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et al [29], Revheim and
Medalia [30]
BGP Patients with moderate to
severe dementia,
institutional setting




how they relate to care
needs in nursing home
patients
Van der Kam et al [31],
Van de Winckel et al
[32]
NCD scale Nursing home patients
with dementia or
learning disabilities




Dijkstra et al [35–37]








of care that is provided
Brickman et al [15], Caro
et al [18], Holtzer et al
[33], Sarazin et al [34],
Stern et al [16]
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nication, and behavior) and was designed to rectify the poten-
tially excessive focus of other instruments on ADL. An
exclusive focus on loss of the ability to perform ADL can
be misleading because it ignores patients with ADwho might
have altered mental states that change their conduct, person-
ality, or communication, but who have no physical disabil-
ities. Instruments that essentially ignore these cognitive and
behavioral changes might miss some of the earliest signs of
a dementing illness [27]. However, acceptance of the RIL
in the mainstream literature seems to be limited. In addition,
no information is available on changes in RIL item scores
over time. Also, the RIL does not provide any indication of
hierarchy among items; the RIL does not distinguish complex
capabilities (eg, managing one’s finances) that AD typically
compromises early in the disease process frommore basic ca-
pabilities (eg, toileting) that typically are affected later on.
The Independent Living Scales (ILS) assessment was de-
signed to provide a broad measure of dependence in patients
with dementia by incorporating cognitive/reasoning skills in
addition to physical measures [28,30]. The ILS is conducted
by a clinician and consists of five subscales and two factor-an-
alyzed subscales. The memory-orientation subscale evaluates
an individual’s ability to recall a list and recognize an object as
well as his or her orientation to time and place. The managing
money subscale includes concrete tasks such as monetary cal-
culations. The managing home and transportation subscale
assesses an individual’s ability to use public transportation
and to perform tasks involved in managing a home, such as
using a telephone. An individual’s awareness of health prob-
lems and potential safety hazards, as well as the ability to han-
dle medical emergencies, is assessed on the health and safetysubscale. Finally, attitudes and concerns regarding interper-
sonal relationships are assessed on the social adjustment sub-
scale. The two factor-analyzed subscales (composed of items
from all five aforementioned subscales) are the performance-
information subscale and the problem-solving subscale.
The ILS differs from other instruments in that the scales
are clinician-driven measures, requiring the patient to per-
form a number of tests that each take 30 to 45 minutes. To
date, the ILS has not been widely used in populations with
dementia, possibly because of the time required to administer
the scales. Also, it is unclear how disease progression can be
measured with the ILS, given the focus on task performance
and the limited information on ordering/scoring of tests over
time.
The Behavioral Rating Scale for Geriatric Patients (BGP)
[31,32] was originally developed in The Netherlands in 1971
as an adaptation of an older scale. The BGP consists of 35
items covering six aspects of patients’ behavior as it pertains
to care in a nursing home setting: helplessness, aggressive be-
havior (eg, threatening behaviors such as beating or kicking),
physical disability (eg, requirement for assistance with eat-
ing, incontinence, the need for restraints or supports to avoid
falling), depressive behavior, mental disability (eg, para-
noia), and inactivity (eg, daytime drowsiness, lack of in-
volvement in useful activities). The items primarily focus
on behaviors that would be problematic from a nursing
care/assistance standpoint, such as additional supervision
needs as a result of inappropriate behaviors or assistance
with basic ADL, and are assessed by an informed respondent,
typically a nurse or a family member.
The BGP-dependency subscale, which consists of a subset
of the original 35 BGP items, has been used in the study of
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[38]. Although the terms used to describe the BGP, especially
the BGP-dependency subscale, are similar to the language
used in this article (eg, care dependency, care needs), the
BGP is focused primarily on patient behavior, and given
the heavy attention paid to behaviors that are more prevalent
in a nursing home situation, it is unlikely that the scale in its
current form would be useful for a population with less
severe AD.
The Nursing Care Dependency (NCD) scale differs from
other measures of dependence in that it was developed on
the basis of nursing theory and specifically assesses a pa-
tient’s degree of reliance on nursing care [35–37]. The
NCD is composed of 15 different dimensions of human
need: eating and drinking, incontinence, body posture, mo-
bility, day/night pattern, getting dressed and undressed,
body temperature, hygiene, avoidance of danger, communi-
cation, contact with others, sense of rules and values, daily
activities, recreational activities, and learning ability. A nurse
who is directly involved in the care of the patient rates the pa-
tient’s degree of dependence for each of these dimensions. In
the short version of the NCD, a 5-point Likert scale is used to
rate each dimension. The longer version of the NCD uses five
written criteria, describing varying degrees of aid required by
a patient, for each dimension of need. The nurse selects the
criterion in each dimension that most accurately describes
the patient’s degree of dependence. By assessing the patient’s
degree of dependence on nursing care, the NCD allows
nurses to better plan individualized patient care.
The primary objective of the Dependence Scale (DS),
which is completed by a reliable informant such as a care-
giver, is to measure the current level of care required by a pa-
tient [16]. The 13 items on the DS range from subtle forms of
dependence, such as the need to be watched or accompanied
outside, to more gross forms, such as the need for assistance
in self-care activities. The instrument is hierarchical in nature,
with the items representing increasing levels of assistance.
For example, item A addresses the need for simple reminders
or advice; item D addresses the ability to independently per-
form household chores; later items address the need for assis-
tance with moving and tube feeding. Items A and B are
scored on a 3-point scale (0 5 never, 1 5 occasionally,
2 5 frequently), items C through M are scored on a 2-point
scale (0 5 no, 1 5 yes). The sum of the scores from the 13
items is used to characterize a patient’s overall dependence,
which is associated with the patient’s living situation and
has been correlated with, but is independent of, measures
of cognition and function [15].
The DS has been used in a number of observational stud-
ies and in trials of AD treatments [15,20,33,34,39–41]. Con-
siderable evidence also supports it as a measure of
dependence (as the concept was described earlier), as charac-
terized by deficits in cognition, function, and behavior. In an
analysis of patients with AD in theMidwestern United States,
Murman et al [20] found that dependence (as measured by the
DS) was a statistically significant mediating/explanatory var-iable between various clinical measures and AD-related
costs. In particular, measures of cognition, behavior, and
other factors predicted a patient’s dependence level, as mea-
sured by the DS, which in turn predicted the patient’s total
AD-related costs, explaining 40% of the variation.3.2. Dependence and economic evaluations of AD
treatments
Attempts to quantify the economic benefits of the treat-
ment of AD with acetylcholinesterase inhibitors or mem-
antine primarily have focused on end points related to
cognition and, rarely, function. However, dependence (or
independence) has, on occasion, been used in economic
evaluations to translate short-term treatment benefits into
long-term consequences. For example, in their cost-effective-
ness model of memantine in Finland, Francois et al [42]
defined health states on the basis of physical dependence,
place of residence, and cognitive function. One of the primary
findings of this model was that memantine therapy was asso-
ciated with approximately 4 extra months of independence.
Caro et al [18] operationally defined dependent on the basis
of two different measures: requirement for .12 hours of
supervision or a DS dependence levelR3. Although this def-
inition allowed for straightforward comparisons of resource
use and quality of life for independent versus dependent
patients and also allowed for calculation of time until a person
was considered dependent, creating a dichotomous variable to
describe what should be a continual process (ie, anAD patient
typically is not independent one day and dependent the next)
limits the utility of this measure for broader applications.4. Summary
Measures currently used to assess AD treatment efficacy
do not meaningfully describe the overall impact of the dis-
ease on patients and their loved ones. To provide a more com-
plete picture of AD, assessment measures should incorporate
aspects of cognitive, functional, and behavioral impairments
and present these factors in a way that multiple audiences can
understand.
Previous research indicates that AD is strongly associated
with increased dependence (reliance on others for care and
basic needs). Dementia is also a risk factor for mortality in
a variety of populations [43]. Compared with individuals
without AD, those with AD can expect to have shorter lives
and spend a greater share of their remaining time dependent
on others.
Previous attempts to describe AD progression in eco-
nomic analyses have partially touched on the idea of depen-
dence as it relates to living situation. For example, in the
recent appraisal document from the United Kingdom’s Na-
tional Institute of Clinical Effectiveness (NICE) [44], a re-
view of potential long-term benefits and costs of
acetylcholinesterase inhibitor use was conducted by using
a model based on patient care requirements, dichotomized
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care.’’ Although the NICE authors noted that this was a gross
oversimplification of AD, they also commented that patient
care needs were the most transparent depiction of AD pro-
gression for determining economic impact. Therefore, further
exploration of patient dependence or care needs with greater
granularity might benefit agencies such as the NICE as they
continue to evaluate AD therapies.
Further research on the concept of dependence might also
provide a more comprehensive, meaningful, and consistent
method for characterizing AD progression from the mild
through the severe disease stages. Loss of independence,
which is gradual during some periods but devastatingly
fast at other times, begins early in the course of AD. Unlike
many other chronic conditions, AD also affects caregivers
and family members in the early stages of the disease, as pa-
tients become increasingly reliant on them. Affected individ-
uals lose the ability to perform certain activities, require
increased supervision, and eventually can no longer live
on their own. This dependence might be an important factor
in predicting patient disability, expenses, and caregiver
stress throughout the course of the disease. Characterizing
typical changes in dependence can help caregivers plan
ahead.
Considering the link between patient dependence and the
need for additional support or care, a measure of this con-
struct presents a relatively straightforward way of translating
clinical changes into units of economic relevance (ie, re-
source use and/or quality of life). Such a construct would
be preferential to those used in previous attempts to model
the relationship between cognition and economic conse-
quences, in which the relationship was weak and difficult
to describe, or even in multiattribute models, which, because
of their complexity, are difficult to interpret and/or communi-
cate. A model based on the concept of increasing dependence
would be useful to policy makers and/or economists in that it
might increase their confidence that changes in resource use
and/or quality of life are indeed due to changes in the measure
of AD progression. Such a model would also be useful to
other audiences (eg, physicians, patients, caregivers) for
which a clear description of the disease path and potential
impact of intervention(s) is not currently available.
A potential limitation of using dependence as a measure of
AD progression is that the amount of assistance required by
a patient might be influenced by non–disease-related factors,
including the individual’s level of care or dependence at
baseline. However, current measures of cognition and func-
tion have similar limitations. For example, measures of func-
tion that review specific activities (eg, meal preparation)
assume a certain level of premorbid functioning that might
not be appropriate for all individuals. Similarly, cognitive ex-
aminations that incorporate word lists or other memory tests
assume a premorbid level of education and/or cognitive abil-
ity that might not apply to everyone. For all these measures,
change from baseline level is the most important gauge of
disease progression. Although individuals might be diag-nosed with AD at different levels of dependence (or cognition
or function), their need for assistance should increase at sim-
ilar rates as their disease progresses.
Another potential issue relates to who should rate a pa-
tient’s dependence level. With the exception of the ILS and
NCD Scale, most measures of dependence identified in the
literature require input from an informant (usually a care-
giver). Although a patient’s primary caregiver should have
the greatest insight into the patient’s daily needs, an indepen-
dent observer would be less likely to be personally affected
by the patient’s dependence. Congruence between caregiver
and/or informant and independent observer assessments of
patient dependence has not yet been established.
These limitations primarily relate to how to best opera-
tionalize the concept of dependence. All instruments that
are currently available and are described in this article have
potential limitations. For example, the BGP-Dependency
and NCD scales were both developed for use in nursing
homes and therefore focus primarily on severe AD. Informa-
tion on the performance of the ILS and RIL and how scores
on these instruments relate to conventional measures of cog-
nition, function, or behavior is sparse or nonexistent; there-
fore, we cannot recommend either of these instruments for
widespread use. More data have been published on the DS,
but because this instrument was not developed by using stan-
dard psychometric techniques, we are unable to comment on
its overall performance. Furthermore, the handling of indi-
vidual items (eg, scoring of the first two items versus all later
items) requires further investigation, as well as the grouping
of certain elements into one item (eg, need for reminders with
chores, shopping, playing games) and further clarification of
the terms used to describe frequency of events (eg, occasion-
ally 5 once per month, frequently 5 once per week). Thus,
because the DS has the most supporting information, in our
opinion it would be considered the most viable candidate
of the instruments identified here. However, the DS still re-
quires further investigation before it can be recommended
for widespread use.
As evidenced by the paucity of instruments and the limited
supporting data for the few available instruments, further de-
velopments in the measurement of dependence would be
valuable. In particular, the development of a new instrument
that incorporates the knowledge gained from the measures
described herein, as well as from review of other measures
of AD progression, would be a valuable addition to the field.
Although it is beyond the scope of this article to develop and/
or test a new measure, the available data suggest that a hierar-
chical scale that encompasses the effect of cognition, func-
tion, and behavior during the entire disease course (ie, from
early through late-stage disease), allows for measurement
of the presence and frequency of symptoms, and is adminis-
tered with minimal time burden on the clinician or caregiver
would be optimal. Scoring should allow for calculation of an
overall level of dependence that can be translated into amean-
ingful description of disease course and should also allow for
flexibility and/or granularity around specific symptoms (eg,
T. McLaughlin et al. / Alzheimer’s & Dementia 6 (2010) 482–493 489acknowledging that different symptoms or even different fre-
quencies of the same symptom can be associated with differ-
ent levels of dependence and support needs). Evidence to
support the linkage between scores on this new scale and con-
ventional measures of cognition or function would be useful
in increasing confidence in its content validity.
AD is a devastating illness, not only for patients but also
for those around them. The disease can have a variety of ef-
fects that might not be adequately reflected by conventional
measures of cognition, function, or behavior. Instead,
a more comprehensive view of the disease and its impact is
needed to more appropriately describe its progression. De-
pendence (or loss of independence) is a potentially useful
concept for describing disease progression in broader terms;
decrements in each of the conventional measures can be as-
sociated with increased dependence, and the concept of lost
independence corresponds to how patients and caregivers
typically view the effect of AD. Measures of dependence
might help clinicians better understand the health, economic,
and pharmacoeconomic impact of AD. Potential measures of
the concept of dependence have been suggested in this arti-
cle. Additional work is needed to refine the concept and to
further validate the current measures or develop new ones.Acknowledgments
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